Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 463 (TSX: $LABS.TO) (CSE: $PLUS.C) (CSE: $THC.C)
Delta, Kelowna, BC, September 3, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
Read this news in full at https://www.investorideas.com/news/2020/cannabis-potcasts/09031LABS-PLUS-THC.asp
Today’s podcast overview/transcript:
Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.
In today’s podcast we look at a few public and private company announcements.
Reformulary Group, an expert-led healthcare company that helps Canadians make sense of medicine (prescription drugs and medical cannabis, announced the launch of its Cannabis Standard™ Index. The Index uniformly categorizes medical cannabis products based on objective data, allowing Canadians and the medical community to find accurate, detailed information and to reliably search and compare products.
"We want to help patients, and their doctors make sense of medical cannabis, so we worked with a group of experts to develop a standardized classification system as is the norm with prescription and over-the-counter drugs, but designed explicitly for cannabinoid-based medicine," said Helen Stevenson, founder and CEO of Reformulary Group. "The Cannabis Standard Index makes it possible for patients and healthcare professionals to search and compare cannabis products and to determine which are similar or interchangeable."
The Index is an educational tool that allows medical cannabis patients and their doctors to assess and compare products made by different Licensed Producers (LPs) using objective data such as composition, format and form rather than strain name. As there are no industry standards for the naming of strains, some producers may apply strain names to products with different concentrations of cannabinoids. By indexing products using objective data, including the presence of major (THC, CBD) and minor cannabinoids (THCA, CBDA, CBG, CBC, CBN) where the information is available, the Index can help guide reliable prescribing and therapeutic substitutions. So, when a medical cannabis patient seeks a change in product type or when a patient's usual LP runs out of stock, they can find an effective alternative.
A national study conducted by RIWI Corp., a global trend-tracking and prediction technology firm, in summer 2019 revealed that two-thirds of medical cannabis patients were interested in a rating system that categorizes cannabis into product types and helps consumers compare products.
[New study underscores importance of medical cannabis rating system: https://reformulary.com/news/new-study-underscores-importance-of-medical-cannabis-rating-system]
The Index is the latest addition to Cannabis Standard, an ecosystem of expert recommendations, patient-powered tools, and independent information to help Canadians and healthcare professionals make smarter, more informed decisions about medical cannabis.
"The addition of the Index to the Cannabis Standard ecosystem empowers patients and healthcare practitioners to access and evaluate medical cannabis with the same level of sophistication as with prescription drugs," said Dr. Alan Bell, family physician and Assistant Professor in the Department of Family and Community Medicine at the University of Toronto.
"Rather than relying on a product strain name, or user-generated reviews, we now have a system to help categorize and differentiate medical cannabis using data relevant for doctors and patients," he added."When medicine makes sense, we all benefit," said Ms. Stevenson, who is the former Assistant Deputy Minister of Health in Ontario. In this role, she ran Ontario's $4 billion drug program, overseeing the Ontario Drug Benefit Formulary. The Cannabis Index borrows from some of the same principles as Reformulary's award-winning DrugFinder™ tool. DrugFinder is broadly offered by Canadian employers to their plan members, and provides patients and plan members with evidence-based information about their medication, empowering them to make informed choices.
The Cannabis Standard Index is free and open source. Reformulary Group endeavors to include products from as many licensed producers as possible. It does not sell cannabis, receives no commissions and does not benefit from the sale of medical cannabis.
MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) today announced that its wholly owned subsidiary MediPharm Labs Inc. will supply premium, formulated cannabis oil to Cann Farm Peru S.A.C., a Lima-based producer and distributor serving Peruvian and other markets in Latin America.
This is MediPharm Labs first such agreement in Latin America and the most recent example of the Company’s international growth strategy in action. As part of this strategy, the Company has expanded its addressable medical, wellness and adult-use markets to parts of Asia Pacific, Europe and now Latin America.
MediPharm Labs is creating footholds in medical, wellness and adult-use markets around the world and in Latin American countries. With a combined population of approximately 580 million - and beginning with its fifth largest country Peru – Latin America factors highly in the Company’s business plan. As an early mover among Latin American countries, Peru has created a legal framework for producing, importing and selling cannabis for medical use. As a result, Peru’s market is advancing rapidly and offers the potential to register varied formats of cannabis based products. Using a range of pricing, consumption and patient datasets, the LATAM Cannabis Report™ by Prohibition Partners(1) forecasts that the LATAM market is expected to exceed US$12 billion by 2028, offering “serious growth potential to global cannabis companies.”
“Peru is one of the top medical cannabis markets in the world and Cann Farm is one of very few cannabis companies which hold both a Droguería licence and cannabis importation licence which makes this agreement of outstanding strategic value to MediPharm Labs,” said Pat McCutcheon, CEO, MediPharm Labs. “As we pursue our global ambitions, it is vital for us to partner with companies of Cann Farm’s calibre who know their local markets intimately, have a real appreciation for the needs of patients, an ongoing commitment to scientific advancement and a sound plan for regional expansion. We expect great things from this collaboration.”
Under the one-year renewable agreement, MediPharm Labs Inc. will provide a variety of cannabis concentrate formats, with optionality for patient ready formulated products. The products will be distributed to patients through pharmacies in Peru. Cann Farm will in turn obtain all Peruvian registrations, authorizations and approvals required for importation. In the future, Cann Farm may look to MediPharm Labs for further support in commercialization activities. MediPharm Labs anticipates delivery to begin in Q4 2020, pending regulatory approval by applicable health authorities.
“Cann Farm was created from our deep commitment to patients, who demand reliable, consistent high quality, and proven product integrity; therefore we choose our partners very carefully,” said Andres Vazquez Vargas, Executive President, Cann Farm Peru. “What impresses us most about MediPharm Labs is their focus on medical markets and their commitment to our production standards, as is seen with their GMP certification, which is the gold standard in pharma production. It’s rare to see GMP certification in the cannabis supply chain because it’s a complex and rigorous process to earn the qualification. This tells us all we need to know about their ability to meet our needs on not only a continuous, but consistent basis.”
● 4 key ingredients to promote a well-rounded night of sleep: THC, CBN, CBD, and just a touch of melatonin.
● All-natural colors and flavors, with only 0.7g of sugar and 5 calories per gummy.
● 2 formulations to offer multiple potential solutions to a wide range of consumers: Sleep Cloudberry, with 5mg of THC, 1mg of CBN, and 1mg of CBD, along with CBNRelief Lychee, with 1mg of THC, 2mg of CBN, and 3mg of CBD.
PLUS’s new SLEEP gummies are scientifically formulated with a precise blend of cannabinoids and melatonin intended to help consumers fall asleep quickly and enjoy a full, restful night’s sleep.
Recent research on the interaction between cannabis, the endocannabinoid system, and the body’s natural circadian rhythm¹ drove PLUS’s formulations of the two new SLEEP products. “Each cannabinoid was selected for how it promotes better sleep, but together they have the potential to be greater than the sum of their parts. This is often referred to as the entourage effect.2 We also included a physiologic dose of melatonin to support our bodies’ circadian rhythm, so these gummies actually work in concert with our natural systems,” stated Dr. Ari Mackler, Chief Scientific Officer.
“We’re excited to help the 71% of cannabis sleep aid users who are not satisfied with their current remedies3,” stated Jake Heimark, CEO and Co-Founder. “Almost 50 million people in the US suffer from insomnia.4 It’s no surprise we hear all the time that one of the top things people look for when they walk into a licensed retailer is something to help them sleep.”
THC BioMed Intl Ltd. (CSE:THC) announced that it has shipped its "Ready to Drink" Cannabis Beverage Shot, THC KISS, to the Ontario Cannabis Store. OCS is the only legal online retailer of recreational cannabis in Ontario.
THC Kiss is also available for purchase in B.C. and Saskatchewan. THC BioMed is in discussion with other provinces to widen its distribution.
THC KISS is a breakthrough Cannabis Beverage Shot that promises to offer a different experience compared to edibles and beverages currently available in either the grey or legal cannabis markets.
THC Kiss aims to be an alternative to smoking cannabis and was developed by THC BioMed using proprietary extraction methods invented by THC BioMed.
"We are proud to bring Canadians a true alternative to smoking cannabis," commented John Miller, president and CEO.
"We continue to receive very positive feedback from consumers. We have received many requests that indicate a high demand for our current products and those in development. THC BioMed continues to deliver a wide array of cannabis products to cater for all classes of cannabis consumers. In addition, all of our products are developed, manufactured and packaged by THC BioMed itself," said Mr. Miller.
Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.
Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
Follow us on Twitter https://twitter.com/Investorideas
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Download our Mobile App for iPhone and Android
Join our Investor Club https://www.investorideas.com/membership/
800 665 0411